Published Date: 23 Apr 2023
The treatment of chronic thromboembolic pulmonary hypertension with balloon pulmonary angioplasty has an evolving safety profile over the years, from 2013 to 2022, as revealed by an analysis of more than two dozen studies.
Read Full NewsIn a new trial, patients with PD-L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.
The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.
1.
New study links air pollution with higher rates of head and neck cancer
2.
FDA OKs Upfront Nivolumab+Chemo for Classic Hodgkin Lymphoma
3.
Big Comeback for Myeloma Drug; DIY Cancer Therapy; Gut Clues to Bladder Cancer
4.
Kate Middleton Gives Cancer Update
5.
FDA Expands Approval of Osimertinib in Lung Cancer
1.
The importance of understanding normal serum osmolality
2.
Colon Cancer Staging: What You Need to Know
3.
AI and Optical Advances: Evolving Blood Cell Morphology Observation in Hematology
4.
RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health
5.
Understanding Adenomyosis: The Role of Ultrasound in Diagnosis Introduction
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
2.
Navigating the Complexities of Ph Negative ALL - Part X
3.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
4.
Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.
5.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation